U.S. markets close in 1 hour 59 minutes

Jaguar Health, Inc. (JAGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2900-0.0020 (-0.68%)
As of 02:00PM EDT. Market open.

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300

Full Time Employees52

Key Executives

NameTitlePayExercisedYear Born
Ms. Lisa A. ConteFounder, CEO, Pres & Director722.54kN/A1959
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. Counsel478.72kN/A1962
Mr. Ian H. Wendt M.B.A.Chief Commercial Officer431.55kN/A1968
Dr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.452.61kN/A1958
Ms. Carol R. LizakChief Financial OfficerN/AN/A1964
Dr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer & Chair of Scientific Advisory BoardN/AN/A1963
Mr. Peter HodgeSr. Director of Investor Relations, Bus. Devel. & Special EventsN/AN/AN/A
Dr. Karen J. Brunke Ph.D.Exec. VP of Corp. & Bus. Devel.N/AN/AN/A
Mr. David SesinChief Manufacturing OfficerN/AN/AN/A
Dr. Michael K. Guy D.V.M., M.S., Ph.D.VP of Preclinical & Nonclinical StudiesN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Corporate Governance

Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.